Drug intelligence / Profile preview

aspirin + desmopressin

Development stage
Unknown
Lead developer
Bayer
Modality
Peptides, Small Molecules
Administration
Oral, Intravenous, Subcutaneous, Intranasal, Rectal, Sublingual
01

Overview

Aspirin + desmopressin is a combination of two drugs with distinct mechanisms of action. Aspirin (acetylsalicylic acid) is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase enzymes, leading to decreased synthesis of thromboxane A2 and thus inhibiting platelet aggregation. Desmopressin is a synthetic analogue of vasopressin that increases plasma levels of coagulation factor VIII and von Willebrand factor, enhancing platelet function and promoting hemostasis. This combination may be considered in clinical scenarios where aspirin-induced bleeding risk needs to be mitigated by the pro-hemostatic effects of desmopressin, such as perioperative management or acute bleeding events in patients on aspirin therapy[2][3][4][6]. The use should be carefully monitored due to potential interactions and increased risk or severity of adverse effects[1][5][7].

02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)AVPR2 (Arginine vasopressin V2 receptor)

Beyond the preview

Go deeper on aspirin + desmopressin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspirin + desmopressin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call